trending Market Intelligence /marketintelligence/en/news-insights/trending/_Bco_wyOs8ditfJFPrHztQ2 content esgSubNav
In This List

US FDA lifts last remaining clinical hold on Prescient drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA lifts last remaining clinical hold on Prescient drug

Prescient Therapeutics Ltd. said the U.S. Food and Drug Administration lifted the clinical hold on the company's trial for PTX-200 in patients with breast cancer.

The company will resume the study in HER2 negative breast cancer patients, the last of three PTX-200 trials paused in May following the death of a patient who experienced liver failure.

The regulator lifted the clinical hold after the company met certain of its guidelines.

The PTX-200 trial for breast cancer will now move on to a phase 2 study. Prior to the hold, the drug cleared a phase 1b study for the same indication.

The U.S. FDA earlier lifted the hold on trials for PTX-200 in patients with acute myeloid leukemia and ovarian cancer.